• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

C4 Therapeutics, Inc. - Common Stock (NQ:CCCC)

3.520 +0.240 (+7.32%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,128,543
Open 3.220
Bid (Size) 3.510 (100)
Ask (Size) 3.550 (100)
Prev. Close 3.280
Today's Range 3.190 - 3.555
52wk Range 1.210 - 3.900
Shares Outstanding 48,797,226
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
C4 Therapeutics to Participate in Upcoming Conferences
May 20, 2026
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 18, 2026
From C4 Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+82.4%
+82.4%
1 Month
+17.7%
+17.7%
3 Month
+84.3%
+84.3%
6 Month
+40.8%
+40.8%
1 Year
+137.8%
+137.8%

More News

Read More
News headline image
C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 12, 2026
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)
April 09, 2026
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma
March 25, 2026
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 09, 2026
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
February 26, 2026
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics to Participate in Upcoming March Conferences
February 23, 2026
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma
February 23, 2026
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 09, 2026
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
February 04, 2026
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 26, 2026
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways
January 14, 2026
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
November 25, 2025
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
November 06, 2025
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering
October 16, 2025
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
October 03, 2025
Via Benzinga
News headline image
C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma
October 01, 2025
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
September 22, 2025
Via Benzinga
News headline image
Forecasting The Future: 4 Analyst Projections For C4 Therapeutics ↗
September 22, 2025
Via Benzinga
News headline image
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
September 20, 2025
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why C4 Therapeutics Stock Crushed the Market on Monday ↗
September 15, 2025
Via The Motley Fool
News headline image
Here are the top movers in Monday's session. ↗
September 15, 2025
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
September 15, 2025
Via Benzinga
News headline image
Which stocks are moving on Monday? ↗
September 15, 2025
Via Chartmill

Frequently Asked Questions

Is C4 Therapeutics, Inc. - Common Stock publicly traded?
Yes, C4 Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does C4 Therapeutics, Inc. - Common Stock trade on?
C4 Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for C4 Therapeutics, Inc. - Common Stock?
The ticker symbol for C4 Therapeutics, Inc. - Common Stock is CCCC on the Nasdaq Stock Market
What is the current price of C4 Therapeutics, Inc. - Common Stock?
The current price of C4 Therapeutics, Inc. - Common Stock is 3.520
When was C4 Therapeutics, Inc. - Common Stock last traded?
The last trade of C4 Therapeutics, Inc. - Common Stock was at 05/21/26 04:00 PM ET
What is the market capitalization of C4 Therapeutics, Inc. - Common Stock?
The market capitalization of C4 Therapeutics, Inc. - Common Stock is 171.77M
How many shares of C4 Therapeutics, Inc. - Common Stock are outstanding?
C4 Therapeutics, Inc. - Common Stock has 172M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap